CURRENT APPROACHES IN CANCER IMMUNOTHERAPY

tibbibiyolojiozel-3-2-25kapak

Metabolic Reprogramming in Immuno-Oncology

Nur ÖZTEN KANDAŞa
aColumbia University Institutional Animal Care and Use Committee, NY, USA

Özten Kandaş N. Metabolic reprogramming in immuno-oncology. Sunguroğlu A, ed. Current Approaches in Cancer Immunotherapy. 1st ed. Ankara: Türkiye Klinikleri; 2025. p.73-8.

ABSTRACT
Immune cells are vital to defense mechanisms against infections and cancerous growth. When these cells recognize signs of danger, they become activated, triggering a cascade of significant alterations in immune responses. Recent studies have revealed that immune cell stimulation also causes metabolic alterations that profoundly affect immune cell activities. Immune cells are strongly affected by metabolic reprogramming, which is significant given their critical role in the growth of malignancies. Thus, it is critical to investigate whether immune cells undergo comparable metabolic reprogramming in the tumor microenvironment and the implications of how metabolic reprogramming affects cancer progression. This study provides a summary of the metabolic reprogramming of immune cells, highlighting the principal pathways involved and their impact on tumor progression.

Keywords: Metabolic reprogramming; tumor microenvironment; immune system

Referanslar

  1. Rodríguez C, Puente-Moncada N, Reiter RJ, Sánchez-Sánchez AM, Herrera F, Rodríguez-Blanco J, et al. Regulation of cancer cell glucose metabolism is determinant for cancer cell fate after melatonin administration. J Cell Physiol. 2021;236(1):27-40. [Crossref]
  2. Boroughs LK, DeBerardinis RJ. Metabolic pathways promoting cancer cell survival and growth. Nat Cell Biol. 2015;17:351-9. [Crossref]  [PubMed]  [PMC]
  3. Mitaishvili E, Feinsod H, David Z, Shpigel J, Fernandez C, Sauane M, et al. The Molecular Mechanisms behind Advanced Breast Cancer Metabolism: Warburg Effect, OXPHOS, and Calcium. Front Biosci (Landmark Ed). 2024;29(3):99. [Crossref]  [PubMed]  [PMC]
  4. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol. 1927;8:519-30. [Crossref]  [PubMed]  [PMC]
  5. Guerra L, Bonetti L, Brenner D. Metabolic Modulation of Immunity: A New Concept in Cancer Immunotherapy. Cell Rep. 2020;32:107848. [Crossref]
  6. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646-74. [Crossref]
  7. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013;39:782-95. [Crossref]
  8. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol. 2010;11:889-96. [Crossref]
  9. Hu C, Xuan Y, Zhang X, Liu Y, Yang S, Yang K. Immune cell metabolism and metabolic reprogramming. Mol Biol Rep. 2022;49:9783-95. [Crossref]  [PubMed]  [PMC]
  10. Navarro C, Ortega Á, Santeliz R, Garrido B, Chacín M, Galban N, et al. Metabolic Reprogramming in Cancer Cells: Emerging Molecular Mechanisms and Novel Therapeutic Approaches. Pharmaceutics. 2022;14. [Crossref]  [PubMed]  [PMC]
  11. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime Rep. 2014;6:13. [Crossref]  [PubMed]  [PMC]
  12. Patel CH, Powell JD. Immune Cell Metabolism and Immuno-Oncology. Annual Review of Cancer Biology. 2023;7:93-110. [Crossref]
  13. Leone RD, Powell JD. Metabolism of immune cells in cancer. Nature Reviews Cancer. 2020;20:516-31. [Crossref]  [PubMed]  [PMC]
  14. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O'Sullivan D, et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013;153:1239-51. [Crossref]  [PubMed]  [PMC]
  15. Biswas SK. Metabolic Reprogramming of Immune Cells in Cancer Progression. Immunity. 2015;43:435-49. [Crossref]
  16. Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14-20. [Crossref]  [PubMed]  [PMC]
  17. Cassetta L, Pollard JW. Tumor-associated macrophages. Curr Biol. 2020;30:R246-R8. [Crossref]
  18. Puthenveetil A, Dubey S. Metabolic reprograming of tumor-associated macrophages. Ann Transl Med. 2020;8:1030. [Crossref]  [PubMed]  [PMC]
  19. Wang S, Liu R, Yu Q, Dong L, Bi Y, Liu G. Metabolic reprogramming of macrophages during infections and cancer. Cancer Lett. 2019;452:14-22. [Crossref]
  20. Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017;5:3-8. [Crossref]  [PubMed]  [PMC]
  21. Mantovani A, Cassatella MA, Costantini C, Jaillon S. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol. 2011;11:519-31. [Crossref]
  22. Stojkov D, Gigon L, Peng S, Lukowski R, Ruth P, Karaulov A, et al. Physiological and Pathophysiological Roles of Metabolic Pathways for NET Formation and Other Neutrophil Functions. Front Immunol. 2022;13:826515. [Crossref]  [PubMed]  [PMC]
  23. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity. 2013;38:633-43. [Crossref]  [PubMed]  [PMC]
  24. Xia L, Oyang L, Lin J, Tan S, Han Y, Wu N, et al. The cancer metabolic reprogramming and immune response. Mol Cancer. 2021;20:28. [Crossref]  [PubMed]  [PMC]
  25. Renner K, Singer K, Koehl GE, Geissler EK, Peter K, Siska PJ, et al. Metabolic Hallmarks of Tumor and Immune Cells in the Tumor Microenvironment. Front Immunol. 2017;8:248. [Crossref]  [PubMed]  [PMC]
  26. Bader JE, Voss K, Rathmell JC. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol Cell. 2020;78:1019-33. [Crossref]
  27. Ganjoo S, Gupta P, Corbali HI, Nanez S, Riad TS, Duong LK, et al. The role of tumor metabolism in modulating T-Cell activity and in optimizing immunotherapy. Front Immunol. 2023;14:1172931. [Crossref]  [PubMed]  [PMC]
  28. Kumagai S, Koyama S, Itahashi K, Tanegashima T, Lin YT, Togashi Y, et al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. 2022;40:201-18.e209.
  29. Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022;13:868695. [Crossref]  [PubMed]  [PMC]
  30. Akalay I, Janji B, Hasmim M, Noman MZ, Thiery JP, Mami-Chouaib F, et al. EMT impairs breast carcinoma cell susceptibility to CTL-mediated lysis through autophagy induction. Autophagy. 2013;9:1104-6. [Crossref]  [PubMed]  [PMC]
  31. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell. 2009;15:195-206. [Crossref]
  32. Kareva I, Hahnfeldt P. The Emerging “Hallmarks” of Metabolic Reprogramming and Immune Evasion: Distinct or Linked? Cancer Research. 2013;73:2737-42. [Crossref]